Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (140) 140
index medicus (96) 96
pharmacokinetics (81) 81
female (71) 71
oncology (71) 71
pharmacology & pharmacy (68) 68
middle aged (59) 59
chemistry, analytical (58) 58
male (58) 58
aged (53) 53
adult (46) 46
cancer (43) 43
mass spectrometry (43) 43
metabolites (38) 38
animals (37) 37
biochemical research methods (37) 37
antineoplastic agents - pharmacokinetics (36) 36
reproducibility of results (36) 36
neoplasms - drug therapy (35) 35
liquid chromatography (29) 29
administration, oral (28) 28
mice (28) 28
chromatography, high pressure liquid - methods (26) 26
analysis (25) 25
sensitivity and specificity (25) 25
tandem mass spectrometry - methods (25) 25
antimitotic agents (24) 24
antineoplastic agents (24) 24
metabolism (23) 23
paclitaxel (23) 23
area under curve (21) 21
plasma (21) 21
infusions, intravenous (20) 20
paclitaxel - administration & dosage (20) 20
paclitaxel - pharmacokinetics (20) 20
pharmacology (20) 20
spectrometry, mass, electrospray ionization - methods (20) 20
neoplasms - metabolism (19) 19
spectroscopy (19) 19
lc-ms/ms (18) 18
phase-i (18) 18
validation (18) 18
antineoplastic agents - blood (17) 17
chromatography, high pressure liquid (17) 17
p-glycoprotein (17) 17
performance liquid-chromatography (17) 17
care and treatment (16) 16
chromatography, liquid - methods (16) 16
research (16) 16
tandem mass-spectrometry (16) 16
therapy (16) 16
antineoplastic agents - administration & dosage (15) 15
antineoplastic agents, phytogenic - pharmacokinetics (15) 15
biological availability (15) 15
chemotherapy (15) 15
docetaxel (15) 15
dose-response relationship, drug (15) 15
calibration (14) 14
pharmacology/toxicology (14) 14
bioanalysis (13) 13
drug administration schedule (13) 13
medicine & public health (13) 13
mice, knockout (13) 13
therapeutic drug monitoring (13) 13
biochemistry & molecular biology (12) 12
human plasma (12) 12
reference standards (12) 12
5-fluorouracil (11) 11
cancer research (11) 11
capecitabine (11) 11
excretion (11) 11
linear models (11) 11
nucleotides (11) 11
ritonavir (11) 11
taxoids - pharmacokinetics (11) 11
topotecan (11) 11
antineoplastic agents - therapeutic use (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
breast neoplasms - drug therapy (10) 10
deoxycytidine - analogs & derivatives (10) 10
dihydropyrimidine dehydrogenase (10) 10
drug (10) 10
drug stability (10) 10
methods (10) 10
taxol (10) 10
treatment outcome (10) 10
tumors (10) 10
usage (10) 10
aged, 80 and over (9) 9
antineoplastic agents - adverse effects (9) 9
antineoplastic agents, phytogenic - administration & dosage (9) 9
bioavailability (9) 9
cells (9) 9
chromatography (9) 9
cisplatin (9) 9
cremophor el (9) 9
dogs (9) 9
in-vitro (9) 9
lc–ms/ms (9) 9
maximum tolerated dose (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration
by Tang, Seng Chuan and Lagas, Jurjen S and Lankheet, Nienke A.G and Poller, Birk and Hillebrand, Michel J and Rosing, Hilde and Beijnen, Jos H and Schinkel, Alfred H
International Journal of Cancer, ISSN 0020-7136, 01/2012, Volume 130, Issue 1, pp. 223 - 233
Sunitinib is an orally active, multitargeted tyrosine kinase inhibitor which has been used for the treatment of metastatic renal cell carcinoma and... 
sunitinib | blood‐brain barrier | P‐glycoprotein | ABC efflux transporters | ABCG2 | blood-brain barrier | P-glycoprotein | TRANSPORTERS | PENETRATION | RECEPTOR | RENAL-CELL CARCINOMA | EFFLUX | PHARMACOKINETICS | ONCOLOGY | IMATINIB | TYROSINE KINASE INHIBITOR | MICE | MULTIDRUG-RESISTANCE | Pyrroles - pharmacokinetics | Drug Resistance, Multiple | Humans | Male | Antineoplastic Agents - administration & dosage | ATP-Binding Cassette Transporters - physiology | Indoles - administration & dosage | Brain - metabolism | Tissue Distribution | Sunitinib | Biological Transport | Pyrroles - administration & dosage | Acridines - administration & dosage | Antineoplastic Agents - pharmacokinetics | ATP Binding Cassette Transporter, Subfamily G, Member 2 | Administration, Oral | Indoles - blood | Pyrroles - blood | Tetrahydroisoquinolines - administration & dosage | Blood-Brain Barrier - drug effects | ATP Binding Cassette Transporter, Subfamily B | Mice, Knockout | Brain - drug effects | ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors | Animals | Dogs | Antineoplastic Agents - blood | Indoles - pharmacokinetics | Mice | ATP Binding Cassette Transporter, Subfamily B, Member 1 - physiology | ATP-Binding Cassette Transporters - antagonists & inhibitors | Medical research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) Formulation and Paclitaxel in Polyethoxylated Castor Oil: A Randomized, Two-Period Crossover Study in Patients With Advanced Cancer
by Slingerland, Marije, MD and Guchelaar, Henk-Jan, PhD and Rosing, Hilde, PhD and Scheulen, Max E., PhD and van Warmerdam, Laurence J.C., PhD and Beijnen, Jos H., PhD and Gelderblom, Hans, PhD
Clinical Therapeutics, ISSN 0149-2918, 2013, Volume 35, Issue 12, pp. 1946 - 1954
Abstract Background Preclinical studies comparing paclitaxel formulated with polyethoxylated castor oil with the sonicated formulation of liposome-entrapped... 
Internal Medicine | Medical Education | paclitaxel | cancer | LEP-ETU | Taxol | liposome | Liposome | Paclitaxel | Cancer | ADVANCED MALIGNANCIES | EFFICACY | INFUSION | ENCAPSULATED PACLITAXEL | THERAPY | PHASE-I TRIAL | TOPOTECAN | PHARMACOLOGY & PHARMACY | CREMOPHOR EL | XENOGRAFTS | Solvents | Castor Oil - analogs & derivatives | Drug Administration Schedule | Humans | Middle Aged | Paclitaxel - adverse effects | Male | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Chemistry, Pharmaceutical | Neoplasms - drug therapy | Cross-Over Studies | Young Adult | Neoplasm Metastasis | Antineoplastic Agents - adverse effects | Adult | Female | Aged | Antineoplastic Agents - pharmacokinetics | Infusions, Intravenous | Liposomes | Paclitaxel - administration & dosage | Therapeutic Equivalency | Care and treatment | Cancer patients | Castor oil | Oncology, Experimental | Drugstores | Research | Studies | School dropouts | Particle size | Hispanic Americans | Cell division | Clinical trials | Lipids | Drug therapy | Pharmaceutical industry | Drug dosages | Cholesterol
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text P‐glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel
by Hendrikx, Jeroen J.M.A and Lagas, Jurjen S and Rosing, Hilde and Schellens, Jan H.M and Beijnen, Jos H and Schinkel, Alfred H
International Journal of Cancer, ISSN 0020-7136, 05/2013, Volume 132, Issue 10, pp. 2439 - 2447
Paclitaxel is avidly transported by P‐glycoprotein (P‐gp/MDR1/ABCB1). This results in low oral bioavailability, which can be boosted by coadministration of... 
P‐glycoprotein (P‐gp/MDR1) | paclitaxel | CYP3A4 | oral bioavailability | ritonavir | P-glycoprotein (P-gp/MDR1) | PLUS CYCLOSPORINE | GUT WALL | PHASE-II | KNOCKOUT MICE | CANCER | MDR1 | INHIBITION | METABOLISM | ONCOLOGY | SYSTEMIC EXPOSURE | ABSORPTION | P-glycoprotein (P-gp | Cytochrome P-450 Enzyme Inhibitors | Area Under Curve | Humans | Cytochrome P-450 Enzyme System - metabolism | Biological Availability | Male | Paclitaxel - pharmacokinetics | Intestinal Absorption | Enzyme Inhibitors - administration & dosage | Antineoplastic Agents, Phytogenic - administration & dosage | Ritonavir - therapeutic use | Ritonavir - pharmacology | Paclitaxel - blood | Paclitaxel - administration & dosage | Antineoplastic Agents, Phytogenic - pharmacokinetics | Taxoids - blood | Antineoplastic Agents, Phytogenic - blood | Ritonavir - administration & dosage | Administration, Oral | Docetaxel | Enzyme Inhibitors - pharmacology | ATP Binding Cassette Transporter, Subfamily B, Member 1 - deficiency | Enzyme Inhibitors - therapeutic use | ATP Binding Cassette Transporter, Subfamily B | ATP Binding Cassette Transporter, Subfamily B, Member 1 - genetics | Mice, Knockout | Taxoids - pharmacokinetics | ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors | ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism | Taxoids - administration & dosage | Cytochrome P-450 Enzyme System - deficiency | Animals | Cytochrome P-450 CYP3A - metabolism | Cytochrome P-450 Enzyme System - genetics | Mice | Infusions, Intravenous | Chemotherapy | Glycoproteins | Bioavailability | Rodents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/mass spectrometry: necessity or not?
by Stokvis, Ellen and Rosing, Hilde and Beijnen, Jos H
Rapid Communications in Mass Spectrometry, ISSN 0951-4198, 02/2005, Volume 19, Issue 3, pp. 401 - 407
It appears to be a general belief that stable isotopically labeled (SIL) internal standards yield better assay performance results for quantitative... 
LC-MS/MS | MATRIX | CHEMISTRY, ANALYTICAL | METABOLITES | HUMAN PLASMA | SPECTROSCOPY | DRUG KAHALALIDE-F | PERFORMANCE | ANTICANCER DRUG | HUMAN URINE | SAMPLES | TANDEM MASS-SPECTROMETRY | Reproducibility of Results | Indoles - analysis | Drug Stability | Formamides - analysis | Anti-Inflammatory Agents, Non-Steroidal - analysis | Enzyme Inhibitors - analysis | Antineoplastic Agents - analysis | Lactones - analysis | Spectrometry, Mass, Electrospray Ionization - standards | Reference Standards | Spectrometry, Mass, Electrospray Ionization - methods | Isotope Labeling | Matrix Metalloproteinase Inhibitors | Mollusk Venoms - analysis | Sulfones - analysis | Acetamides - analysis | Depsipeptides - analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Upfront genotyping of DPYD∗2A to individualize fluoropyrimidine therapy: A safety and cost analysis
by Deenen, Maarten J and Meulendijks, Didier and Cats, Annemieke and Sechterberger, Marjolein K and Severens, Johan L and Boot, Henk and Smits, Paul H and Rosing, Hilde and Mandigers, Caroline M.P.W and Soesan, Marcel and Beijnen, Jos H and Schellens, Jan H.M
Journal of Clinical Oncology, ISSN 0732-183X, 01/2016, Volume 34, Issue 3, pp. 227 - 234
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry
by Martínez-Chávez, Alejandra and Rosing, Hilde and Hillebrand, Michel and Tibben, Matthijs and Schinkel, Alfred H and Beijnen, Jos H
Analytical and Bioanalytical Chemistry, ISSN 1618-2642, 8/2019, Volume 411, Issue 20, pp. 5331 - 5345
A novel method was developed and validated for the quantification of the three approved CDK4/6 inhibitors (abemaciclib, palbociclib, and ribociclib) in both... 
Biochemistry, general | Plasma | Food Science | Palbociclib | Ribociclib | Laboratory Medicine | Tissue homogenates | Abemaciclib | LC-MS/MS | Chemistry | Analytical Chemistry | Monitoring/Environmental Analysis | Characterization and Evaluation of Materials | CHEMISTRY, ANALYTICAL | LC-MS | TISSUE | BIOCHEMICAL RESEARCH METHODS | QUANTITATIVE-ANALYSIS | PD 0332991 | CANCER | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Purines - pharmacology | Humans | Pyridines - analysis | Benzimidazoles - analysis | Piperazines - pharmacology | Animals | Piperazines - analysis | Protein Kinase Inhibitors - analysis | Aminopyridines - pharmacology | Benzimidazoles - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | Purines - analysis | Pyridines - pharmacology | Chromatography, Liquid - methods | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Tandem Mass Spectrometry - methods | Aminopyridines - analysis | Ethylenediaminetetraacetic acid | Liquid chromatography | Spectrum analysis | Analysis | Liver | Methods | Brain | Matrices (mathematics) | Correlation coefficients | Tissues | Small intestine | Cyclin-dependent kinase 4 | Blood plasma | Pretreatment | Spleen | Correlation coefficient | Spectroscopy | Elution | Kidneys | Ions | Mass spectroscopy | Stability analysis | Calibration | Chromatography | Dilution | Inhibitors | Human performance | Storage conditions | Acetonitrile | Scientific imaging | Mass spectrometry | Research Paper
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
by Henricks, Linda M and Lunenburg, Carin A T C and de Man, Femke M and Meulendijks, Didier and Frederix, Geert W J and Kienhuis, Emma and Creemers, Geert-Jan and Baars, Arnold and Dezentjé, Vincent O and Imholz, Alexander L T and Jeurissen, Frank J F and Portielje, Johanna E A and Jansen, Rob L H and Hamberg, Paul and ten Tije, Albert J and Droogendijk, Helga J and Koopman, Miriam and Nieboer, Peter and van de Poel, Marlène H W and Mandigers, Caroline M P W and Rosing, Hilde and Beijnen, Jos H and Werkhoven, Erik van and van Kuilenburg, André B P and van Schaik, Ron H N and Mathijssen, Ron H J and Swen, Jesse J and Gelderblom, Hans and Cats, Annemieke and Guchelaar, Henk-Jan and Schellens, Jan H M
The Lancet Oncology, ISSN 1470-2045, 11/2018, Volume 19, Issue 11, pp. 1459 - 1467
Fluoropyrimidine treatment can result in severe toxicity in up to 30% of patients and is often the result of reduced activity of the key metabolic enzyme... 
5-FLUOROURACIL SENSITIVITY | ORAL CAPECITABINE | VARIANTS | ONCOLOGY | DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY | FLUOROURACIL PLUS LEUCOVORIN | PHASE-III | RISK | SEVERE TOXICITY | PHARMACOGENETICS IMPLEMENTATION CONSORTIUM | METASTATIC COLORECTAL-CANCER | Cancer patients | Care and treatment | Safety and security measures | Health aspects | Analysis | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Predictive Value of Microdose Pharmacokinetics
by van Nuland, Merel and Rosing, Hilde and Huitema, Alwin D R and Beijnen, Jos H
Clinical pharmacokinetics, 04/2019, Volume 58, Issue 10, pp. 1221 - 1236
Phase 0 microdose trials are exploratory studies to early assess human pharmacokinetics of new chemical entities, while limiting drug exposure and risks for... 
Index Medicus
Journal Article
Details down arrow
9. Full Text Multidrug Transporter ABCG2/Breast Cancer Resistance Protein Secretes Riboflavin (Vitamin B2) into Milk
by Antonius E. van Herwaarden and Els Wagenaar and Gracia Merino and Johan W. Jonker and Hilde Rosing and Jos H. Beijnen and Alfred H. Schinkel
Molecular and Cellular Biology, ISSN 0270-7306, 02/2007, Volume 27, Issue 4, pp. 1247 - 1253
Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley... 
BCRP | ABCG2 GENE | BIOCHEMISTRY & MOLECULAR BIOLOGY | ORAL BIOAVAILABILITY | DRUGS | METHOTREXATE | IDENTIFICATION | BCRP/ABCG2 | EXPRESSION | XENOTOXINS | P-GLYCOPROTEIN | CELL BIOLOGY | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Milk - chemistry | Flavin-Adenine Dinucleotide - blood | Lactation | Male | Riboflavin - pharmacokinetics | Tritium | Flavin-Adenine Dinucleotide - analysis | Riboflavin - analysis | Neoplasm Proteins - metabolism | Tissue Distribution | Biological Transport | Flavin Mononucleotide - analysis | Riboflavin - secretion | ATP-Binding Cassette Transporters - metabolism | Female | Flavin Mononucleotide - blood | Riboflavin - chemistry | Sex Characteristics | Biotin - analysis | Animals | Mammary Glands, Animal - metabolism | Milk - secretion | Dogs | Mammary Glands, Animal - secretion | Mice
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity
by Meulendijks, Didier and Henricks, Linda M and Jacobs, Bart A W and Aliev, Abidin and Deenen, Maarten J and de Vries, Niels and Rosing, Hilde and van Werkhoven, Erik and de Boer, Anthonius and Beijnen, Jos H and Mandigers, Caroline M P W and Soesan, Marcel and Cats, Annemieke and Schellens, Jan H M
British Journal of Cancer, ISSN 0007-0920, 04/2017, Volume 116, Issue 11, pp. 1415–1424 - 1424
BACKGROUND: We investigated the predictive value of dihydropyrimidine dehydrogenase (DPD) phenotype, measured as pretreatment serum uracil and dihydrouracil... 
5-fluorouracil | toxicity | capecitabine | uracil | dihydropyrimidine dehydrogenase | fluoropyrimidines | Fluoropyrimidines | Dihydropyrimidine dehydrogenase | Capecitabine | Toxicity | Uracil | RATIOS | DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY | CHEMOTHERAPY | PLASMA | COLORECTAL-CANCER PATIENTS | PHARMACOKINETICS | ONCOLOGY | DIHYDROURACIL | DPD DEFICIENCY | DPYD VARIANTS | Predictive Value of Tests | Capecitabine - metabolism | Prospective Studies | Humans | Middle Aged | Male | Young Adult | Dihydropyrimidine Dehydrogenase Deficiency - complications | Neoplasms - blood | Dihydropyrimidine Dehydrogenase Deficiency - genetics | Fluorouracil - adverse effects | Drug-Related Side Effects and Adverse Reactions - genetics | Aged, 80 and over | Pharmacogenomic Variants | Adult | Female | Fluorouracil - metabolism | Uracil - blood | Thymidylate Synthase - metabolism | Genotype | Hospitalization | Biomarkers - blood | Pharmacogenomic Testing | Thymidylate Synthase - genetics | Neoplasms - drug therapy | Phenotype | Capecitabine - adverse effects | Alleles | Antimetabolites, Antineoplastic - adverse effects | Leukocytes, Mononuclear - enzymology | Aged | Drug-Related Side Effects and Adverse Reactions - mortality | Dihydrouracil Dehydrogenase (NADP) - metabolism | Dihydrouracil Dehydrogenase (NADP) - genetics | Uracil - analogs & derivatives | Index Medicus | Translational Therapeutics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel
by Iusuf, Dilek and Henikx, Jeroen J M A and van Esch, Anita and van de Steeg, Evita and Wagenaar, Els and Rosing, Hilde and Beijnen, Jos H and Schinkel, Alfred H
International Journal of Cancer, ISSN 0020-7136, 01/2015, Volume 136, Issue 1, pp. 225 - 233
Organic anion transporting polypeptides (human: OATPs and mouse: Oatps) are uptake transporters with important roles in drug pharmacokinetics and toxicity. We... 
Humans | Antineoplastic Agents | Male | Organic Anion Transporters, Sodium-Independent | Genetic Complementation Test | Chemistry, Pharmaceutical | Intestinal Absorption | Polysorbates | Mice, Knockout | Animals | Organic Anion Transporters | Biological Transport | Taxoids | OATP1A/1B | OATP1B3 | organic anion transporting polypeptides (OATPs) | docetaxel | OATP1B1 | DRUG | ANION-TRANSPORTING POLYPEPTIDES | CANCER | MOUSE MODELS | DISPOSITION | PACLITAXEL | POLYMORPHISMS | PHARMACOKINETICS | ONCOLOGY | SLCO1B3 | EXPRESSION | Taxoids - metabolism | Antineoplastic Agents - administration & dosage | Taxoids - pharmacokinetics | Antineoplastic Agents - metabolism | Taxoids - administration & dosage | Organic Anion Transporters - physiology | Polysorbates - administration & dosage | Antineoplastic Agents - pharmacokinetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Solute Carrier Organic Anion Transporter Family Member 1B3 | Organic Anion Transporters, Sodium-Independent - physiology | Antimitotic agents | Genetic engineering | Surface active agents | Antineoplastic agents | Biopolymers | Proteins | Plasma | Chemotherapy | Pharmacology | Rodents | Liver | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment
by Jurjen S. Lagas and Robert A.B. van Waterschoot and Vicky A.C.J. van Tilburg and Michel J. Hillebrand and Nienke Lankheet and Hilde Rosing and Jos H. Beijnen and Alfred H. Schinkel
Clinical Cancer Research, ISSN 1078-0432, 04/2009, Volume 15, Issue 7, pp. 2344 - 2351
Purpose: Imatinib, a BCR-ABL tyrosine kinase inhibitor, is a substrate of the efflux transporters P-glycoprotein (P-gp; ABCB1 ) and ABCG2 (breast cancer... 
P-glycoprotein | Dasatinib | Brain Accumulation | Pharmacokinetics | ABCG2 | CHRONIC MYELOGENOUS LEUKEMIA | CYTOGENETIC RESPONSES | IN-VITRO | ONCOLOGY | PHILADELPHIA-CHROMOSOME | ACUTE LYMPHOBLASTIC-LEUKEMIA | BLAST CRISIS | BCR-ABL | GASTROINTESTINAL STROMAL TUMORS | IMATINIB MESYLATE | CHRONIC MYELOID-LEUKEMIA | Thiazoles - metabolism | Thiazoles - blood | Pyrimidines - blood | Pyrimidines - metabolism | Thiazoles - pharmacokinetics | Antineoplastic Agents - metabolism | Brain - metabolism | ATP Binding Cassette Transporter, Subfamily B, Member 1 | ATP-Binding Cassette Transporters - genetics | Biological Transport | Antineoplastic Agents - pharmacokinetics | Protein Kinase Inhibitors - pharmacokinetics | ATP Binding Cassette Transporter, Subfamily G, Member 2 | Cell Line | Tetrahydroisoquinolines - pharmacology | Protein Kinase Inhibitors - blood | ATP Binding Cassette Transporter, Subfamily B | Mice, Knockout | Animals | Acridines - pharmacology | Dogs | Antineoplastic Agents - blood | Pyrimidines - pharmacokinetics | Mice | ATP-Binding Cassette Transporters - antagonists & inhibitors | Protein Kinase Inhibitors - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Exposure‐Response Assessment of Enzalutamide and Its Major Metabolites in a Real‐World Cohort of Patients with Metastatic Castration‐Resistant Prostate Cancer
by Nuland, Merel and Bergman, Andries M and Rosing, Hilde and Vries, Niels and Huitema, Alwin D.R and Beijnen, Jos H
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, ISSN 0277-0008, 12/2019, Volume 39, Issue 12, pp. 1137 - 1145
Study Objective Enzalutamide is an oral agent for the treatment of metastatic castration‐resistant prostate cancer (mCRPC); N‐desmethyl enzalutamide is its... 
toxicity | prostate‐specific antigen | exposure | metabolites | response | enzalutamide
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text The Breast Cancer Resistance Protein Protects against a Major Chlorophyll-Derived Dietary Phototoxin and Protoporphyria
by Johan W. Jonker and Marije Buitelaar and Els Wagenaar and Martin A. van der Valk and George L. Scheffer and Rik J. Scheper and Torsten Plösch and Folkert Kuipers and Ronald P.J. Oude Elferink and Hilde Rosing and Jos H. Beijnen and Alfred H. Schinkel
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 11/2002, Volume 99, Issue 24, pp. 15649 - 15654
The breast cancer resistance protein (BCRP/ABCG2) is a member of the ATP-binding cassette family of drug transporters and confers resistance to various... 
Diet | Phototoxicity | Bone marrow | Mice | Alfalfa | Lesions | Chlorophylls | Porphyrins | Bile | Food | OVEREXPRESSION | MITOXANTRONE | GENE | METABOLISM | MULTIDISCIPLINARY SCIENCES | TOPOTECAN | PORPHYRINS | CELL-LINES | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Diet - adverse effects | Porphyria, Hepatoerythropoietic - therapy | Chlorophyll - analogs & derivatives | Fetus - metabolism | Topotecan - toxicity | Medicago sativa - adverse effects | Porphyria, Hepatoerythropoietic - prevention & control | Chlorophyll - pharmacokinetics | Chromatography, High Pressure Liquid | Porphyrins - metabolism | Porphyrins - pharmacokinetics | ATP-Binding Cassette Transporters - physiology | Chlorophyll - administration & dosage | Photosensitizing Agents - administration & dosage | ATP-Binding Cassette Transporters - genetics | Neoplasm Proteins | Bone Marrow Transplantation | Female | Molecular Structure | Porphyria, Hepatoerythropoietic - genetics | Protoporphyrins - chemistry | Dermatitis, Phototoxic - etiology | Fibroblasts - metabolism | Chlorophyll - toxicity | Cell Line | Genetic Predisposition to Disease | Administration, Oral | Protoporphyrins - blood | Radiation Chimera | Mice, Inbred Strains | Dermatitis, Phototoxic - prevention & control | Mice, Knockout | Pregnancy | Drug Resistance - genetics | Animals | Photosensitizing Agents - toxicity | Topotecan - pharmacokinetics | Photosensitizing Agents - pharmacokinetics | Porphyria | Chlorophyll | Breast cancer | Research | Drug resistance | Photobiology | Antineoplastic agents | Antimitotic agents | Testolactone | Proteomics | Physiological aspects | Molecular biology | Observations | Photosensitivity disorders | Erythrohepatic porphyria | Adenosine triphosphate | Biological Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Development, validation, and clinical application of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of total intracellular [beta]-decitabine nucleotides and genomic DNA incorporated [beta]-decitabine and 5-methyl-2'-deoxycytidine
by Roosendaal, Jeroen and Rosing, Hilde and Lucas, Luc and Oganesian, Aram and Schellens, Jan H.M and Beijnen, Jos H
Journal of Pharmaceutical and Biomedical Analysis, ISSN 0731-7085, 02/2019, Volume 164, p. 16
DNA hypermethylation is an epigenetic event that is commonly found in malignant cells and is used as a therapeutic target for [beta]-decitabine ([beta]-DEC)... 
Medical research | Epigenetic inheritance | Nucleotides | Antineoplastic agents | Antimitotic agents | Pyrimidines | Methyltransferases | DNA | Medicine, Experimental | Genetic research | Methylation | Mass spectrometry | High performance liquid chromatography
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Electrospray Ionization Quadrupole Ion-Mobility Time-of-Flight Mass Spectrometry as a Tool to Distinguish the Lot-to-Lot Heterogeneity in N-Glycosylation Profile of the Therapeutic Monoclonal Antibody Trastuzumab
by Damen, Carola W.N and Chen, Weibin and Chakraborty, Asish B and van Oosterhout, Mike and Mazzeo, Jeffrey R and Gebler, John C and Schellens, Jan H.M and Rosing, Hilde and Beijnen, Jos H
Journal of the American Society for Mass Spectrometry, ISSN 1044-0305, 2009, Volume 20, Issue 11, pp. 2021 - 2033
Monoclonal antibodies are typically glycosylated at asparagine residues in the Fc domain, and glycosylation heterogeneity at the Fc sites is well known. This... 
Biotechnology | Chemistry | Analytical Chemistry | Bioinformatics | Proteomics | Organic Chemistry | RECOMBINANT ANTIBODY | CHEMISTRY, ANALYTICAL | HUMAN-IGG | CHEMISTRY, PHYSICAL | CHARGE HETEROGENEITY | LINKED OLIGOSACCHARIDES | IDENTIFICATION | CANCER-THERAPY | SPECTROSCOPY | CARBOHYDRATE ANALYSIS | LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | CAPILLARY-ELECTROPHORESIS | IMMUNOGLOBULIN-G | Protein Structure, Tertiary | Antibodies, Monoclonal, Humanized | Antibodies, Monoclonal - analysis | Time Factors | Spectrometry, Mass, Electrospray Ionization - methods | Mass Spectrometry | Glycosylation | Chromatography, Liquid - methods | Tandem Mass Spectrometry - methods | Antibodies, Monoclonal - chemistry | Trastuzumab | Antimitotic agents | Asparagine | Monoclonal antibodies | Drugstores | Antineoplastic agents | Mass spectrometry | Health aspects | Spectroscopy | Ionic mobility | Ions | Abundance | Quadrupoles | Glycan | Heterogeneity | Electrospraying | Ionization | Scientific imaging | Mass spectra
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights